RxDoctor Payments DataLook up a doctor →

Ashley Dietrich, MD

Dermatology · Milwaukee, WINPI 1780030825

Payments from drug & device makers

$465,761in general payments, 2019–2025

Across 1,502 payments — averaging $310.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$365K
  • Sanofi$41K
  • Regeneron Healthcare Solutions, Inc.$32K
  • Galderma Laboratories, L.p.$16K
  • Sun Pharmaceutical Industries Inc.$3K
  • Lilly USA, LLC$1K
  • plus $8K from 31 others

What the payments were for

  • Consulting fees$5,5571%
  • Speaking & faculty fees$384,76183%
  • Travel & lodging$49,01611%
  • Food & beverage$25,6936%
  • Education$7340%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$465,761 in reported general payments places this provider in the 95th percentile of 260 dermatology providers in Wisconsin.

See all dermatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$301,138
Medicare patients
291
Services billed
3,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab160$640,840
RinvoqUpadacitinib92$598,377
Humira(Cf) PenAdalimumab11$159,146
OtezlaApremilast32$151,237
Clobetasol Propionate200$7,033
Pimecrolimus14$3,583
Triamcinolone Acetonide141$1,764
Ketoconazole94$1,693
Doxycycline Hyclate91$1,513
Tretinoin12$1,510
Fluocinolone AcetonideFluocinolone/Shower Cap17$1,190
Tacrolimus11$1,022
Minoxidil61$867
Hydroxyzine Hcl72$795
Doxycycline Monohydrate27$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$365,154$598,37792 claims
AmgenOtezla$483$151,23732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 260 dermatology providers in Wisconsin.

Other dermatology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →